As of July 2022, biosimilar Nyvepria (pegfilgrastim-apgf) launched at an average sales price of 16 percent higher than Neulasta's ASP, while the biosimilar drug Fulphila (pegfilgrastim-jmdb) launched at an average sales price of six percent less than Neulasta's. This statistic illustrates the wholesale acquisition cost and average sales price of Neulasta (pegfilgrastim) biosimilars in the United States.
Advertisement
Advertisement
Wholesale acquisition cost (WAC) and average sales price (ASP) of Neulasta (pegfilgrastim) biosimilars in the United States as of 2022
Product
WAC
ASP
Fulphila (pegfilgrastim-jmdb) injection
-33%
-6%
Udenyca (pegfilgrastim-cbqv)
-33%
-5%
Ziextenzo (pegfilgrastim-bmez)
-37%
-6%
Nyvepria (pegfilgrastim-apgf)
-37%
16%
Add this content to your personal favorites. These can be accessed from the favorites menu in the main navigation.
You have no right to use this feature.
Make sure to contact us if you are interested in scientific citation.
You can upgrade your account to enable this functionality for all statistics.
This feature is not available with your current account.Request access
Learn more about how Statista can support your business.
Amgen. (October 31, 2022). Wholesale acquisition cost (WAC) and average sales price (ASP) of Neulasta (pegfilgrastim) biosimilars in the United States as of 2022 [Graph]. In Statista. Retrieved June 26, 2025, from https://www.statista.com/statistics/1275671/wac-and-asp-of-neulasta-pegfilgrastim-biosimilars-us/
Amgen. "Wholesale acquisition cost (WAC) and average sales price (ASP) of Neulasta (pegfilgrastim) biosimilars in the United States as of 2022." Chart. October 31, 2022. Statista. Accessed June 26, 2025. https://www.statista.com/statistics/1275671/wac-and-asp-of-neulasta-pegfilgrastim-biosimilars-us/
Amgen. (2022). Wholesale acquisition cost (WAC) and average sales price (ASP) of Neulasta (pegfilgrastim) biosimilars in the United States as of 2022. Statista. Statista Inc.. Accessed: June 26, 2025. https://www.statista.com/statistics/1275671/wac-and-asp-of-neulasta-pegfilgrastim-biosimilars-us/
Amgen. "Wholesale Acquisition Cost (Wac) and Average Sales Price (Asp) of Neulasta (Pegfilgrastim) Biosimilars in The United States as of 2022." Statista, Statista Inc., 31 Oct 2022, https://www.statista.com/statistics/1275671/wac-and-asp-of-neulasta-pegfilgrastim-biosimilars-us/
Amgen, Wholesale acquisition cost (WAC) and average sales price (ASP) of Neulasta (pegfilgrastim) biosimilars in the United States as of 2022 Statista, https://www.statista.com/statistics/1275671/wac-and-asp-of-neulasta-pegfilgrastim-biosimilars-us/ (last visited June 26, 2025)
Wholesale acquisition cost (WAC) and average sales price (ASP) of Neulasta (pegfilgrastim) biosimilars in the United States as of 2022 [Graph], Amgen, October 31, 2022. [Online]. Available: https://www.statista.com/statistics/1275671/wac-and-asp-of-neulasta-pegfilgrastim-biosimilars-us/
Advertisement
Profit from additional features with an Employee Account
Please create an employee account to be able to mark statistics as favorites.
Then you can access your favorite statistics via the star in the header.
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
